<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532452</url>
  </required_header>
  <id_info>
    <org_study_id>2015-4184</org_study_id>
    <nct_id>NCT02532452</nct_id>
  </id_info>
  <brief_title>Third Party Viral Specific T-cells (VSTs)</brief_title>
  <official_title>Third Party Viral Specific T-cells (VSTs) for Treatment of Viral Infections in Immunocompromised Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that viral specific T-cells (a type of white&#xD;
      blood cell) can be generated from an unrelated donor and given safely to patients with viral&#xD;
      infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Viral reactivation and infection is a major cause of morbidity in immunocompromised patients&#xD;
      (including HSCT recipients). In this study we will draw blood from unrelated (third party)&#xD;
      donors and use the blood to generate viral specific T-cells (VSTs) with specificity for&#xD;
      Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus (ADV), BK virus (BKV), and JC&#xD;
      Virus. The VSTs will be infused into immunocompromised children with specific viral&#xD;
      infections (EBV, CMV, ADV, BKV , or JC virus). Cells will be selected for infusion based on&#xD;
      the recipient's HLA type and the viral specificity of the cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2015</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful production of viral specific T-cells</measure>
    <time_frame>Within 30 days post culture initiation</time_frame>
    <description>Of the patients who had a VST culture initiated, successful production of VST cells is defined as meeting the protocol-defined release criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients who do not have infusional toxicity</measure>
    <time_frame>Through 30 minutes post infusion</time_frame>
    <description>Patients will be monitored for infusional toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of GVHD associated with VST infusion</measure>
    <time_frame>Through 30 days after infusion</time_frame>
    <description>Patients will be monitored for the development of VST associated GVHD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of viral-specific T-cells</measure>
    <time_frame>At 30 days after infusion</time_frame>
    <description>Presence of viral-specific T-cells in the participant's blood will be assessed by Elispot assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral burden</measure>
    <time_frame>At 30 days after infusion</time_frame>
    <description>The viral burden will be assessed using the protocol-defined efficacy assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Viral Infection</condition>
  <condition>Viral Reactivation</condition>
  <condition>Infection in an Immunocompromised Host</condition>
  <arm_group>
    <arm_group_label>Viral Specific VST Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3rd party VST infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Viral Specific VST Infusion</intervention_name>
    <description>3rd party VSTs will be infused into immunocompromised patients who have evidence of viral infection or reactivation defined as any of the following:&#xD;
Blood adenovirus PCR ≥ 1,000&#xD;
Blood CMV PCR ≥ 500&#xD;
Blood EBV PCR ≥ 9,000&#xD;
Plasma BKV PCR &gt;1,000&#xD;
Plasma JC Virus PCR &gt; 1,000&#xD;
Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites.&#xD;
Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis&#xD;
Evidence of EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies.&#xD;
Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy.&#xD;
Evidence of PML or other CNS infection due to JC virus.</description>
    <arm_group_label>Viral Specific VST Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Immunocompromised patient with evidence of viral infection or reactivation&#xD;
&#xD;
          -  Age &gt;1 day&#xD;
&#xD;
          -  Recipients who have had a stem cell transplant must be at least 21 days after stem&#xD;
             cell infusion&#xD;
&#xD;
          -  Clinical status must allow tapering of steroids to &lt; 0.5mg/kg prednisone or other&#xD;
             steroid equivalent&#xD;
&#xD;
          -  Must be able to receive CTL infusion in Cincinnati&#xD;
&#xD;
          -  Informed consent obtained by PI or sub-investigator either in person or by phone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active acute GVHD grades II-IV&#xD;
&#xD;
          -  Uncontrolled bacterial or fungal infection&#xD;
&#xD;
          -  Uncontrolled relapse of malignancy&#xD;
&#xD;
          -  Infusion of ATG or alemtuzumab within 2 weeks of VST infusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Grimley, MD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamie Wilhelm</last_name>
    <phone>(513) 803-1102</phone>
    <email>Jamie.Wilhelm@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Grimley, MD</last_name>
    <email>Michael.Grimley@cchmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Grimley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>August 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2015</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epstein-Barr Virus (EBV)</keyword>
  <keyword>Adenovirus (ADV)</keyword>
  <keyword>Cytomegalovirus (CMV)</keyword>
  <keyword>T-Cells</keyword>
  <keyword>Donor</keyword>
  <keyword>BK virus (BKV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

